CD133 在乳腺癌新辅助化疗后的表达及其临床意义简

目的探讨分化抗原簇蛋白133（CDl33）表达与新辅助化疗（NAC）化学敏感性的关系。方法对51例原发性乳腺癌患者在NAC治疗前后分别采用免疫组化方法检测CDl33表达，观察NAC治疗前后CDl33的差异性。结果CDl33与病理完全缓解率（pCR）存在明显相关性（P=0．023）。NAC治疗后临床完全缓解率及部分缓解率（cCR4-cPR）达到82．4％（42／51），病理反应2级＋3级达到54．9％，pCR31．3％（16／51）。CDl33表达与乳腺癌淋巴结转移有关（P=0．042）；CDl33（＋）在pCR方面明显低于CDl33（-）（P=0．035）；病理1级者较2级或3级更易出现CDl33（＋）（P=0．002）。CDl33（＋）在NAC治疗后57．1％（20／41）高于NAC治疗前47．1％（24／51），NAC治疗前后均为CDl33（-）与病理反应有效率（2级）呈正相关关系（P〈0．001）。同样，经NAC治疗后，8例CDl33（4-）转为CDl33（-），其与病理有效率亦呈正相关关系（P=0．019）。结论CDl33可以作为一种有效标志物来预测NAC治疗乳腺癌的化学敏感性。

The expression of CD133 in breast cancer after neoadjuvant chemotherapy and its clinical significance.

Objective To identify CD133 expression by immunohistoehemical staining testing before and after neoadjuvant chemotherapy （NAC） treatment and to diseuss the relationship between chemical sensitivity of CD133 expression and NAC treatment. Methods To observe the difference of CD133 using method to detect CD133 expression with 51 primary breast cancer patients before and after NAC treatment, respeetively. Results CD133 is obviously relevant of pCR （ P = 0. 023 ）. The rate of eCR ＋ cPR reached 82.4% （42/51） after NAC treatment. The rate of pathological reaetion level 2 ＋ 3 reaehed 54.9%, pCR31.3% （ 16/51 ）. CD133 expression is associated with breast cancer lymph node metastasis （ P =0. 042）. The PCR expression in CD133 （ ＋ ） was lower than that of CD133 （ - ） （ P =0. 035 ）. Pathologi- eal grade 1 is more likely to appear CD133 （ ＋ ） compared with level 2 or level 3 （ P =0. 002）. CD133 （ ＋ ） was 57.1% （20/41） after NAC treatment, which was more than 47.1% （24/51 ） before the NAC treatment. CD133 （ - ） has a positive correlation with pathological reaction effi- eieney （ level 2） （ P 〈 O. 001 ）. 8 eases with CD133 （ ＋ ） translated into CD133 （ - ） , whieh also had a positively correlation with pathological efficient （ P = O. 019）. Conclusion CD133 can serve as an effective marker to predict the NAC chemical sensitivity for breast cancer patient.